Opioid receptor subtypes may have site-specific effects and play different roles in modulating serotonergic neurotransmission in the mammalian central nervous system. To test this hypothesis, we used in vivo microdialysis to measure changes in extracellular serotonin (5-hydroxytryptamine; 5-HT) in response to local infusion of -, ␦-, and -opioid receptor ligands into the dorsal raphe nucleus (DRN), median raphe nucleus (MRN), and nucleus accumbens (NAcc) of freely behaving rats ]enkephalin (DPDPE), and deltophin-II into the DRN also increased extracellular 5-HT, an effect that was blocked by selective ␦-receptor antagonists. In contrast to the DRN, local infusion of -and ␦-opioids had no effect on 5-HT in the MRN or NAcc. These data indicate that -and ␦-opioid ligands have a selective influence on serotonergic neurons in the DRN. Finally, the -receptor
]enkephalin (DPDPE), and deltophin-II into the DRN also increased extracellular 5-HT, an effect that was blocked by selective ␦-receptor antagonists. In contrast to the DRN, local infusion of -and ␦-opioids had no effect on 5-HT in the MRN or NAcc. These data indicate that -and ␦-opioid ligands have a selective influence on serotonergic neurons in the DRN. Finally, the -receptor agonist U-50,488 [trans-(Ϯ)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide] produced similar decreases in 5-HT during local infusion into the DRN, MRN, and NAcc. These results provide evidence of differential regulation of 5-HT release by opioid receptor subtypes in the midbrain raphe and forebrain.
The largest population of serotonergic cell bodies is located in the dorsal raphe nucleus (DRN) within the ventral portion of periaqueductal gray (PAG), an area richly endowed with opioids and involved in integrating responses to stress (Basbaum and Fields, 1984) . Pain and stressful stimuli activate opioidergic neurons in the PAG, which in turn may modulate the activity of serotonergic neurons with projections to sites involved in arousal and emotional state (Ma and Han, 1992; Grahn et al., 1999) . Immunocytochemical (Kalyuzhny et al., 1996) and neurochemical (Tao and Auerbach, 1995) studies provide further evidence that opioids modulate serotonergic neuronal activity. However, single unit recording data suggest that the opioid receptor agonist morphine does not directly stimulate serotonergic neurons (Haigler, 1978) . Instead, opioids may inhibit both inhibitory and excitatory afferents to the DRN (Jolas and Aghajanian, 1997) and thus could indirectly affect the pattern of serotonergic neuronal discharge.
Four types of opioid receptors, , ␦, , and ORL-1, have been identified on the basis of pharmacological and molecular criteria (Knapp et al., 1995; Neal et al., 1999) . Endogenous ligands for opioid receptors have been determined, and these have distinct, albeit overlapping, patterns of distribution in the CNS (Mansour et al., 1995; Martin-Schild et al., 1999; Neal et al., 1999) . In particular, the ventral PAG, which encompasses the DRN, has moderate to high densities of each of the endogenous opioids and corresponding opioid receptor types (Mansour et al., 1995; Neal et al., 1999) . Moreover, there are distinctive and in some instances opposing physiological effects of selective agonists of the four opioid receptor types. For example, selective -opioid receptor agonists are strong analgesics but produce greater physical dependence relative to selective ␦-opioid receptor agonists (Maldonado et al., 1990) . In contrast, -and ORL-1 receptor agonists induce hyperalgesia (Lutfy and Maidment, 2000) and can reverse the analgesic effects of -opioid receptor activation (Pan et al., 1997) .
In this study, we used in vivo microdialysis to test the hypothesis that different opioid receptor subtypes have distinct and site-specific roles in regulation of serotonergic neurons. We compared the effect of -, ␦-and -opioid-receptor ligands on extracellular levels of 5-HT in the CNS. Anesthetics that alter glutamate or GABA transmission attenuate the effect of morphine on analgesia (Banks et al., 1988) and 5-HT turnover and release (Rivot et al., 1988; Tao and Auerbach, 1994a) . Thus, we used freely behaving rats to avoid interference by anesthetics with the afferent neurons that may indirectly mediate the effects of opioids. Opioids were infused into the DRN by reverse microdialysis. To determine whether there are regionally selective effects on 5-HT, opioids were also infused into the median raphe nucleus (MRN), which contains the second largest cluster of serotonergic cell bodies, and the nucleus accumbens (NAcc), a forebrain site innervated by projections from the DRN and implicated in addiction, sensitization, and other behavioral consequences of opiate drugs.
Materials and Methods
Animal Preparation. Male Sprague-Dawley rats purchased from Harlan (Indianapolis, IN) were individually housed with food and water available ad libitum. The animals were kept on a reversed light/dark cycle (lights off from 9:30 AM to 9:30 PM), and all experiments were performed during the dark phase. All animal use procedures were in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Rutgers University Institutional Review Board. Rats weighing 300 to 350 g were anesthetized with a combination of xylazine (4 mg/kg i.p.) and ketamine (80 mg/kg i.p.), and guide cannulas (21-gauge stainless steel tubing) were implanted using standard stereotaxic techniques. After surgery, the guide cannulas were plugged with stylets and the rats were allowed a recovery period of at least 1 week.
Microdialysis Procedures. Microdialysis was performed with a concentric design probe constructed from 26-gauge stainless steel tubing and glass silica. The dialysis tubing was hollow nitrocellulose fiber (0.25 mm o.d., 13,000 mol. wt. cut-off; Spectrum Medical Industries, Los Angeles, CA). The dialysis membrane exchange surface was 1 mm for probes in the DRN and MRN, and 2.5 mm in the NAcc. Stereotaxic coordinates for the DRN were: AP 1.2, DV 6.1 to 6.7, and ML Ϯ0.4 at a 32°angle lateral to the midline; in the MRN: AP 1.2, DV 8.2 to 8.6, and ML Ϯ0.5 at a 26°angle lateral to the midline; in NAcc: AP 10.7, DV 6.0 to 8.5, and ML 1.4 (Paxinos and Watson, 1986) . Most experiments used conventional microdialysis techniques with a single probe implanted in the DRN, MRN or NAcc. In some "dual probe" experiments, one dialysis probe in the NAcc was used to sample changes in extracellular 5-HT in response to opioid infusion through a second dialysis probe implanted in the area of serotonergic cell bodies in the DRN.
Dialysis probes were implanted at the beginning of the lights-on period, ϳ12 h before the start of microdialysis sampling. Rats were briefly immobilized with ethyl ether, and the dialysis probes were inserted into the target site via the guide cannulas and secured with dental cement. Rats were then placed in the test chamber, and attached to a counterweighted cable and swivel that allowed animals to move freely and have access to food and water. Immediately after implantation, the probes were perfused with a modified, buffered Ringer solution containing 140 mM NaCl, 3.0 mM KCl, 1.5 mM CaCl 2 , 1.0 mM MgCl 2 , 0.27 mM NaH 2 PO 4 , 1.2 mM Na 2 HPO 4 , pH 7.4. This solution (artificial cerebrospinal fluid; aCSF) was pumped at a rate of 1.05 l/min. To increase the reliability of 5-HT detection, a selective 5-HT reuptake inhibitor, citalopram (1 M), was added to the aCSF. Citalopram at a concentration of 1 M in the aCSF produces a small elevation in extracellular 5-HT, which does not strongly activate autoreceptors or inhibit 5-HT release under our experimental conditions . Moreover, citalopram did not qualitatively alter the effects of experimental manipulations such as blocking GABA A receptors or systemic administration of opioids. Thus, local infusion of bicuculline into the DRN produced a 3-fold increase in extracellular 5-HT irrespective of the presence of a 5-HT reuptake inhibitor . Also, systemic morphine produced an ϳ50% increase in forebrain levels of extracellular 5-HT with or without citalopram in the aCSF, and this effect was less variable with reuptake blocked (Tao and Auerbach, 1994b) .
Samples were collected every 30 min during the lights-off period and analyzed by high-performance liquid chromatography with electrochemical detection. Separation of 5-HT was achieved on a 10 cm ϫ 3.2 mm column with ODS 3 m packing (BAS Bioanalytical Systems Inc., West Lafayette, IN). The mobile phase composition was 0.12 M NaOH, 0.18 mM EDTA, 0.15 M monochloroacetic acid, 1.0 mM sodium octane sulfonic acid, and 56 ml/l acetonitrile, pH 3.4, and was pumped at a rate of 0.90 ml/min. Monoamines were measured using a dual potentiostat electrochemical detector (PerkinElmer Life Sciences, Boston, MA) and dual glassy carbon electrode in the parallel configuration. Applied potentials relative to an Ag/AgCl electrode were set at approximately maximal and half-maximal for oxidation of 5-HT. These values were checked frequently and were usually about 590 and 540 mV. The detection limit for 5-HT was approximately 0.3 pg/sample based on a signal-to-noise ratio of 3:1.
After extracellular levels of 5-HT were stable in four consecutive samples (less than Ϯ10% variation), opioid receptor ligands were administered by reverse dialysis infusion. Ligands were dissolved in the aCSF at concentrations based on microdialysis studies of the effects of opioids on extracellular dopamine in the rat CNS (Spanagel et al., 1990) . Also, we used analgesiometry to evaluate the physiological significance of the concentrations that we used (see below).
Analgesia Measurements. The analgesic effect of reverse dialysis infusion of DAMGO in the DRN was determined using the tail-flick test. For this experiment, a separate group of rats was used with the major aim of determining whether the concentration of DAMGO was in a physiologically relevant range. A secondary aim was to determine whether analgesia was correlated with opioidinduced changes in 5-HT. The rats were kept in the dialysis chamber overnight and aCSF (containing 1 M citalopram) was infused into the DRN via a probe. Analgesia measurements were carried out the next day during the lights-off period under dim red light illumination. The room temperature (22 Ϯ 0.5°C) and humidity were thermostatically controlled. Once every 15 min, rats were transferred from the dialysis chamber to an analgesiometer (Ugo Basile, Varese, Italy) to determine tail-flick latencies during continuous infusion of aCSF into the DRN. The radiant intensity was set to maintain basal flick latencies in the range of 3.9 to 4.9 s with the cut-off time set at 12 s to avoid cumulative damage to tissue. After three trials averaged as the baseline, DAMGO was added to the aCSF and infused into the DRN for 2 h. Latency measurements were carried out every 15 min during the period of drug infusion, and one final measurement was taken 2 h after the end of the drug infusion period.
Data Analysis. For determining changes in extracellular 5-HT, the four consecutive samples before drug administration were averaged to obtain mean basal levels expressed as picograms per sample. Baseline levels were also normalized to 100% with changes induced by drug treatments expressed as a percentage of mean basal levels and plotted against sample time in the figures. Absolute amounts of baseline 5-HT (picograms per sample) are presented in the figure legends. For analgesic experiments, the data were expressed as the latency of tail withdrawal in response to radiant heat stimulation. Significance of differences (p Ͻ 0.05) was determined using repeated measures analysis of variance, followed by Scheffé's post hoc test.
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Effect of -Opioid Receptor Ligands on 5-HT.
DAMGO is a synthetic peptide selective for -opioid receptors (Knapp et al., 1995) . Reverse dialysis infusion of DAMGO (100 -1000 M) into the DRN for 2 h elicited dosedependent increases in extracellular levels of 5-HT in the DRN (Fig. 1A) . The mean maximal effect was an ϳ80% increase above baseline, and levels returned to baseline ϳ2 h after the end of infusion. Two endogenous -opioid peptides, endomorphin-1 and endomorphin-2 (Zadina et al., 1997) were also infused for 2 h into the DRN. Endomorphin-1 (300 M) produced an ϳ70% increase in 5-HT in the DRN (Fig. 1B) . At the same concentration, endomorphin-2 produced an ϳ40% increase in extracellular 5-HT. The difference between the effects of endomorphin-1 and endomorphin-2 was not statistically significant. Extracellular 5-HT returned to baseline levels within 1 h of the end of endomorphin infusion.
␤-FNA is a selective antagonist of -opioid receptors (Recht and Pasternak, 1987) . Reverse dialysis infusion of ␤-FNA alone at the concentration of 300 M had no effect on 5-HT in the DRN, but blocked DAMGO-induced increases in 5-HT ( Fig. 2A) . In contrast, infusion of a ␦-opioid selective receptor antagonist, ICI-174,864, had no effect on DAMGO-induced increases in 5-HT (Fig. 4) . In a separate dual-probe experiment, DAMGO was infused into the DRN to determine whether this elicited parallel changes in 5-HT efflux in the DRN and NAcc. As shown in Fig. 2B , DAMGO infusion into the DRN produced significant in- [F (3,20) ϭ 2.36, P Ͼ 0.05]. DAMGO induced a dose-dependent increase in 5-HT [F (3,20) ϭ 11.95, P Ͻ 0.0001]. The maximum increases (changes from baseline in picograms/sample) were: 100 M DAMGO, 0.9 Ϯ 0.4 from baseline 3.3 Ϯ 0.7; 300 M DAMGO, 3.2 Ϯ 0.6 from baseline 3.8 Ϯ 0.5; and 1000 M DAMGO, 4.7 Ϯ 0.5 from baseline 5.9 Ϯ 1.4. B, baseline levels of 5-HT in the DRN between groups were not significantly different [F (2,18) ϭ 1.14, P Ͼ 0.05]. Infusion of endomorphin-1 induced a significant increase in 5-HT [F (1,12) ϭ 10.10, P Ͻ 0.01]. The maximum increase was 2.6 Ϯ 0.8 from baseline 3.7 Ϯ 0.7 pg/sample. Endomorphin-2 also produced a significant increase in 5-HT [F (1,10) ϭ 5.02, P Ͻ 0.05]. The maximum increase was 2.3 Ϯ 0.8 from baseline 5.2 Ϯ 1.3 pg/sample. The effects of endomorphin-1 and endomorphin-2 were not significantly different [F (1,14) ϭ 2.09, P ϭ 0.17]. Asterisks indicating significance were omitted from the graphs for the sake of clarity. creases in extracellular 5-HT in both the DRN and the NAcc. In contrast, infusion of aCSF in the DRN had no effect on 5-HT in the NAcc.
Effect of ␦-Opioid Receptor Ligands on 5-HT. The enkephalin analog DADLE (300 -1000 M) was infused by reverse dialysis into the DRN and induced a significant, ϳ40% increase in 5-HT in the DRN (Fig. 3A) . DADLE binds to both the putative ␦ 1 -and ␦ 2 -opioid receptor subtypes (Xu et al., 1998) , which may have differential functions in regulating neuronal activity (Acosta and Lopez, 1999) . Hence, we examined the role of ligands selective for either the ␦ 1 -or ␦ 2 -opioid receptor subtypes. The enkephalin analog, DPDPE, preferentially binds to the putative ␦ 1 -opioid receptor subtype (Acosta and Lopez, 1999) . Infusion of DPDPE (1000 M) into the DRN produced a significant, ϳ40% increase in DRN 5-HT (Fig. 3B) . Another enkephalin analog, deltorphin II, is selective for the putative ␦ 2 -opioid receptor subtype (Acosta and Lopez, 1999) . Reverse dialysis infusion of deltorphin II (1000 M) into the DRN also produced an ϳ40% increase in DRN 5-HT (Fig. 3B) . Thus, ␦ 1 -and ␦ 2 -receptor ligands had similar effects on 5-HT, and the effect of a nonselective ␦-opioid agonist was not the sum of the effects of the ␦ 1 -and ␦ 2 -opioid receptor agonists.
To determine whether these changes in 5-HT were receptor-specific, the ␦-opioid antagonist ICI-174,864 (300 M) was infused into the DRN beginning 30 min before DADLE. Reverse dialysis infusion of ICI-174,864 alone at a concentration of 300 M had no effect on DRN 5-HT, but blocked the effect of DADLE (Fig. 4) . ICI-174,864 may also act as an inverse agonist for ␦-opioid receptors (Chiu et al., 1996; Neilan et al., 1999) , and consistent with this possibility, at a concentration of 1000 M in the aCSF, ICI-174,864 induced a significant decrease in DRN 5-HT (Fig. 5A) . Naltrindole, a putatively pure antagonist of ␦-opioid receptors (Chiu et al., 1996; Neilan et al., 1999 ) also induced a reduction in 5-HT in the DRN, and this effect was dose-dependent (Fig. 5B) . In contrast, 5-HT in the DRN was not reduced during infusion of the -opioid receptor antagonist ␤-FNA at a concentration of 1000 M in the aCSF (data not shown).
Effect of a -Opioid Receptor Agonist on 5-HT in the DRN. In contrast to -and ␦-opioid receptor agonists, a -opioid elicited decreases in extracellular 5-HT. Thus, reverse dialysis infusion of the nonpeptide -agonist U-50,488 (100, 300, and 1000 M) into the DRN produced a dosedependent decrease in extracellular 5-HT in the DRN (Fig.  6A ). Decreases were significant beginning 1 h after the start of U-50,488 infusion. The -receptor antagonist nor-BNI (300 M) alone had no effect on DRN 5-HT, but blocked the U-50,488-induced decrease in 5-HT (Fig. 6B) .
Effect of a -Opioid on 5-HT in the MRN and NAcc: Comparison with -and ␦-Opioids. The results of infusing -, ␦-, and -opioid receptor agonists into the MRN and NAcc were compared with effects in the DRN. As shown in Fig. 7 , the -agonist, U-50,488 produced decreases in extracellular 5-HT during reverse dialysis infusion into the MRN and NAcc. Similar to the effect of U-50,488 in the DRN, the decreases in 5-HT in the MRN and the NAcc were significant, beginning 1 h after the start of drug infusion (Fig. 7, A and B) . In contrast, infusion of the -opioid agonist DAMGO or the ␦-opioid agonist DPDPE into the MRN and the NAcc did not affect 5-HT in these sites (Fig. 7, A, C, and D) . Although there was a small, transient increase in 5-HT during infusion of DPDPE (1000 M) into the NAcc, this effect was not significant (Fig. 7D) .
Nociceptive Response to DAMGO during Microdialysis Infusion. The microdialysis membrane is a barrier to free diffusion of substances into and out of the microdialysis probe. Thus, during reverse dialysis infusion of opioids, the concentration in extracellular space is much lower than in the perfusion medium. To determine whether the concentrations that we used resulted in physiologically relevant levels, a separate group of rats was used for measurement of changes in tail-flick latency in response to infusion of DAMGO through a dialysis probe in the DRN. DAMGO at a concentration of 100 M in the infusion medium had no significant effect on tail-flick latency compared with the baseline measurement of 4.5 s or controls infused with aCSF alone (Fig. 8) . Tail-flick latency was significantly increased to ϳ8 s during infusion of DAMGO at a concentration of 300 M in the aCSF, and DAMGO at 1000 M increased latency nearly to the cut-off time of 12 s. However, in contrast to the sustained effect on extracellular 5-HT, tail-flick latency decreased markedly during the second hour of DAMGO infusion, and baseline values were obtained within 2 h after the end of infusion. Thus, the dose-response curves for DAMGO-induced increases in tail-flick latency and extracellular levels of 5-HT were similar, but there was a dissociation between the time course of the two effects. A, baseline levels were 9.3 Ϯ 2.1 and 5.7 Ϯ 0.7 pg/sample for the 300 and 1000 M ICI-174,846 groups, respectively, and 5.9 Ϯ 1.1 pg/sample for the aCSF control group. Baseline levels of 5-HT were not significantly different between groups [F (2,14) ϭ 1.89, P Ͼ 0.05]. Infusion of ICI-174,864 produced a significant reduction in 5-HT [F (2,14) ϭ 5.54, P Ͻ 0.02]. As compared with baseline levels, the decreases in 5-HT were 1.9 Ϯ 0.5 and 1.4 Ϯ 1.3 pg/sample in response to 300 and 1000 M ICI-174,864, respectively. B, baseline levels were 3.0 Ϯ 0.3, 4.6 Ϯ 1.3, and 5.0 Ϯ 1.1 pg/sample for the 30, 100, and 300 M naltrindole groups, respectively, and 5.7 Ϯ 1.3 pg/sample for the aCSF control group. Baseline levels of 5-HT were not significantly different between groups [F (3,14) ϭ 1.08, P Ͼ 0.05]. Naltrindole induced a significant reduction in 5-HT in the DRN [F (3,14) ϭ 6.21, P Ͻ 0.01]. As compared with baseline levels, the maximum decreases in 5-HT were 0.3 Ϯ 0.2, 1.8 Ϯ 1.1, and 2.2 Ϯ 0.7 pg/sample in response to 30, 100, and 300 M naltrindole, respectively. ૺ, p Ͻ 0.05, Scheffé's post hoc test. 
Modulation of 5-HT Efflux by Opioid Receptor Subtypes
553
Discussion
These results demonstrate that -opioids in the DRN can elicit increases in 5-HT efflux in the DRN and the NAcc of unanesthetized rats. ␦-Opioids in the DRN also produced increases in 5-HT efflux. In contrast, -and ␦-opioids had no effect on 5-HT when infused into the MRN or NAcc. These results are consistent with other reports that systemic administration of morphine elicits selective increases in 5-HT in forebrain sites innervated by the DRN (Spampinato et al., 1985; Tao and Auerbach, 1995) . In contrast, -receptor agonists decreased 5-HT during infusion into the DRN, MRN, or NAcc. Thus, -, ␦-, and -opioid receptors may have different roles and sites of action in regulation of 5-HT neurotransmission in the CNS.
-Opioids. DAMGO infusion into the DRN increased extracellular 5-HT. ␤-FNA, a -receptor antagonist, but not ICI-174,864, a ␦-opioid antagonist, blocked this effect, indicating that -opioid receptors mediated DAMGO-induced increases in 5-HT. Because concentrations of DAMGO were high, this may be particularly relevant to the pharmacological effects of -opioids. However, endogenous opioids are abundant in the ventral PAG/DRN and mediate responses to stress (Grahn et al., 1999) . Moreover, we found that the endogenous peptides, endomorphin-1 and endomorphin-2, also induced increases in 5-HT in the DRN. Compared with the synthetic opioid DAMGO, the increase in response to endomorphin-2 was somewhat smaller, and both endomorphin-1 and endomorphin-2 had shorter-lasting effects. This 8 . Changes in tail-flick latency in response to DAMGO infusion into the DRN. Tail-flick latency (mean Ϯ S.E.M., n ϭ 6) was measured before (BL; baseline), during, and after drug infusion into the DRN. The cut-off time was set at 12 s. DAMGO in the DRN produced a dose-dependent increase in latency [F (3,20) jpet.aspetjournals.org may be attributable to faster metabolic clearance of the endomorphins, although we cannot exclude other possibilities such as differences in efficacy without data concerning the effects of higher doses of these two endogenous peptides.
DAMGO infusion into the DRN also increased extracellular 5-HT in the NAcc, which is innervated by serotonergic projections from the DRN. Similarly, morphine infusion into the DRN increased extracellular 5-HT in the NAcc (Tao and Auerbach, 1995) . Conversely, tetrodotoxin infusion into the DRN decreased extracellular 5-HT in the DRN and NAcc . This indicates that 5-HT release in the raphe (from axon collaterals or dendrites) parallels changes in forebrain projection sites and depends on action potential propagation from serotonergic cell bodies. Together, these data suggest that extracellular levels in the raphe can be used as an indicator of neuronal activity and 5-HT release in the forebrain.
The DRN and surrounding ventrolateral PAG are involved in the analgesic effects of opioids (Basbaum and Fields, 1984) . Thus, to determine whether opioids were administered in a physiological concentration range, we measured the analgesic response to reverse dialysis infusion of DAMGO in the DRN. Similar to the effect on extracellular 5-HT, we observed elevated tail-flick latencies only at concentrations of DAMGO above 100 M in the aCSF. In comparison, direct microinjection of 50 ng of DAMGO into the ventral PAG elicited analgesia (Pan et al., 2000) . This suggests that reverse dialysis of DAMGO at concentrations of 100 to 1000 M in the aCSF bracketed the physiologically effective range for this peptide. The concentration of a substance added to the aCSF falls steeply after crossing out of the dialysis probe and approaches zero at a distance of ϳ1 mm (Dykstra et al., 1992) . Thus, compared with microinjection, administration by reverse dialysis requires high drug concentrations for effective perfusion of surrounding tissue. Moreover, in contrast to the effect of infusion into the DRN, morphine infusion into the MRN at a site ϳ1 mm below the DRN did not increase 5-HT in the NAcc (Tao and Auerbach, 1995) . The NAcc is innervated by serotonergic projections from the DRN but not the MRN. Thus, these data support the conclusion that drug diffusion was limited to a small area around the dialysis probe.
Although the dose-response curves for elevations in 5-HT and tail-flick latency were similar, the time courses were different. Despite sustained increases in extracellular 5-HT, tail-flick latencies returned toward baseline during DAMGO infusion. This suggests that enhanced activity of serotonergic neurons in the DRN is not sufficient in mediating the analgesic effects of opioids. Because changes in extracellular 5-HT provide only an indirect and summed measure of release, it is possible that a subpopulation of serotonergic neurons is involved in modulation of nociception (Mason, 1999) . However, the elevation in tail-flick latency produced by opioids in the ventral PAG has been more definitively linked to activation of glutamatergic neurons with projections to the medulla (Fields et al., 1991) .
The observation that DAMGO and endomorphins enhanced extracellular 5-HT contrasts with electrophysiological evidence that opioids have inhibitory effects (North, 1986) and do not increase serotonergic neuronal discharge in the DRN (Haigler, 1978) . This may be explained by evidence that the effects of -opioids on 5-HT are indirectly mediated by inhibition of GABAergic neurons in the ventral PAG (Kalyuzhny et al., 1996; Jolas and Aghajanian, 1997) . Thus, -opioids could have a disinhibitory influence similar to their effect on dopaminergic neurons (Johnson and North, 1992) . However, -opioids also inhibit glutamatergic afferents (Jolas and Aghajanian, 1997). By inhibiting both GABAergic and glutamatergic input, -opioids might regularize serotonergic neuronal discharge. Although GABA-mediated decreases in discharge would be blocked, the maximal instantaneous rate of serotonergic neuronal discharge could be unchanged or even decreased because the excitatory influence of glutamate is also inhibited. The net effect of -opioids would be an increase in extracellular 5-HT because GABA but not glutamate has a strong tonic influence on serotonergic neurons in the DRN under our experimental conditions (Tao et al., 1996; . This hypothesis is supported by evidence that blocking GABA receptors in the DRN abolishes increases in 5-HT elicited by morphine and DAMGO (Tao and Auerbach, 1994a; unpublished results) . In contrast, GABA does not have a strong tonic influence on 5-HT in the MRN (Tao et al., 1996; . This could explain the observation that infusion of -opioids into the MRN had no effect on extracellular 5-HT. The physiological significance of the effect of opioids on DRN but not MRN serotonergic neurons is difficult to assess. However, based in part on established functions of serotonergic neurons, this may contribute to the changes in behavioral state such as interruption of normal sleep cycles produced by opioids (Jacobs and Fornal, 1991) .
␦-Opioids. ␦-Opioid receptor agonists also produced increases in 5-HT in the DRN but not in the MRN or NAcc. In addition, the ␦-receptor antagonist ICI-174,864 blocked the effect of DADLE, but not DAMGO. These results support the conclusion that the effects of ␦-agonists on 5-HT were mediated by ␦-opioid receptors. A common pool of G i/o proteins may transduce the effects of -and ␦-opioids (Alt et al., 2002) , and it is possible that both receptor subtypes increase 5-HT by a similar disinhibitory mechanism. Our observation that ␦-opioid receptor agonists had smaller effects on 5-HT efflux may be related to the much weaker inhibition of GABAergic afferents by DADLE compared with DAMGO (Jolas and Aghajanian, 1997) .
In contrast to the -antagonist ␤-FNA, naltrindole and ICI-174,864 by themselves at high concentrations reduced 5-HT efflux in the DRN. This is interesting in relation to in vitro evidence that ␦-receptors, unlike other opioid receptor subtypes, can be active in the absence of agonist. Moreover, ICI-174,864 acted as an inverse agonist to reduce constitutive activity of cloned ␦-opioid receptors expressed in kidney and glioma cell lines (Chiu et al., 1996; Neilan et al., 1999) . In contrast, naltrindole acted in vitro on cloned ␦-receptors as a pure antagonist (Chiu et al., 1996; Neilan et al., 1999) . It is conceivable that both naltrindole and ICI-174,864 inhibit constitutive activity of ␦-opioid receptors in vivo and, thus, reduce 5-HT efflux. Alternatively, endogenous ␦-opioids may have a tonic excitatory influence on serotonergic neurons under our experimental conditions. Further experiments are necessary to evaluate these hypotheses and exclude the possibility that ICI-174,864 and naltrindole at high concentrations had nonselective effects on 5-HT efflux.
We also investigated the role of putative ␦-opioid receptor subtypes in regulation of 5-HT release. DPDPE and deltorphin II have been used as selective ␦ 1 -and ␦ 2 -receptor agonists, respectively (Acosta and Lopez, 1999) . However, the two agonists produced similar increases in extracellular 5-HT. Conceivably, the two ␦-receptor subtypes contribute independently to modulation of 5-HT release, but the effect of the nonselective ␦-agonist, DADLE, did not have a greater effect than DPDPE or deltorphin II. Thus, the increase in response to DADLE cannot be ascribed to the sum of ␦ 1 -and ␦ 2 -receptor effects.
-Opioids. In contrast to -and ␦-opioids, -opioids reduced extracellular 5-HT in all brain areas examined. -Opioids inhibited 5-HT efflux from spinal cord synaptosomes, suggesting a direct effect on nerve endings (Monroe et al., 1995) . -Opioids also decreased, whereas and ␦ agonists enhanced, extracellular dopamine (Spanagel et al., 1990) . It is interesting to note that the effects of -opioids on both 5-HT and dopamine were delayed. For dopamine, this has been ascribed to delayed enhancement of dopamine reuptake rather than inhibition of release (Thompson et al., 2000) . The possibility that -opioids act at the site of nerve endings to either enhance 5-HT clearance or inhibit exocytosis could explain the observation that -opioids had no effect on electrophysiological properties of serotonergic neurons (Jolas and Aghajanian, 1997) .
In conclusion, the present results demonstrate that different opioid receptor types have distinct functions in regulating synaptic levels of 5-HT. -and ␦-Opioid receptor agonists in the DRN but not MRN enhanced 5-HT efflux. In contrast, -agonists acted in the DRN, MRN, and forebrain to decrease extracellular 5-HT. Thus, -opioids may act directly on serotonergic nerve endings, whereas -and ␦-opioids presumably act indirectly by inhibiting afferents to serotonergic neurons in the DRN (Tao and Auerbach, 1994a; Jolas and Aghajanian, 1997) . These results support the conclusion that -, ␦-, and -opioids differentially modulate serotonergic neurotransmission in specific CNS sites implicated in general control of arousal state and specific behaviors such as drug self-administration.
